Emergence of serotype 10A-ST11189 among pediatric invasive pneumococcal diseases, South Korea, 2014-2019
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yun, Ki Wook | - |
dc.contributor.author | Rhie, Kyuyol | - |
dc.contributor.author | Kang, Jin Han | - |
dc.contributor.author | Kim, Kyung-Hyo | - |
dc.contributor.author | Ahn, Jong Gyun | - |
dc.contributor.author | Kim, Yae-Jean | - |
dc.contributor.author | Eun, Byung Wook | - |
dc.contributor.author | Oh, Sung Hee | - |
dc.contributor.author | Cho, Hye-Kyung | - |
dc.contributor.author | Hong, Young Jin | - |
dc.contributor.author | Kim, Nam Hee | - |
dc.contributor.author | Kim, Yun-Kyung | - |
dc.contributor.author | Lee, Hyunju | - |
dc.contributor.author | Lee, Taekjin | - |
dc.contributor.author | Kim, Hwang Min | - |
dc.contributor.author | Cho, Eun Young | - |
dc.contributor.author | Kim, Chun Soo | - |
dc.contributor.author | Park, Su Eun | - |
dc.contributor.author | Oh, Chi Eun | - |
dc.contributor.author | Jo, Dae Sun | - |
dc.contributor.author | Song, Eun Song | - |
dc.contributor.author | Lee, Jina | - |
dc.contributor.author | Choi, Jae Hong | - |
dc.contributor.author | Lee, Joon Kee | - |
dc.contributor.author | Lee, Hoan Jong | - |
dc.contributor.author | Choi, Eun Hwa | - |
dc.date.accessioned | 2021-10-01T03:40:57Z | - |
dc.date.available | 2021-10-01T03:40:57Z | - |
dc.date.created | 2021-09-07 | - |
dc.date.issued | 2021-09-24 | - |
dc.identifier.issn | 0264-410X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/82276 | - |
dc.description.abstract | Replacement with nonvaccine serotypes (NVTs) among invasive pneumococcal diseases (IPDs) after the introduction of extended-valency pneumococcal conjugate vaccines varies in predominant serotypes across countries. This study analyzed changes in serotype distribution through serotyping, multilocus sequence typing, and antimicrobial susceptibility testing of 168 pediatric IPD isolates obtained from a multihospital-based surveillance system during 2014–2019 in South Korea. Vaccine serotypes (VTs) accounted for 16.1% (19A, 10.1%; 6A, 1.8%; and 19F 1.8%), 82.1% were NVTs (10A, 23.8%; 15A, 8.3%; 12F, 6.5%; 15C, 6.5%; and 15B, 6.0%), and three (1.8%) were nontypeable. Serotype 10A was the most common serotype, with a significant increase from 11.5% in 2014 to 33.3% in 2019 (p < 0.05 for the trend). Other NVTs decreased from 70.4% to 41.7% between 2015 and 2019, most notably in serotype 12F (from 14.8% to 0%). Almost all (95.0%) serotype 10A isolates were ST11189, which were multidrug resistant. © 2021 | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCI LTD | - |
dc.relation.isPartOf | Vaccine | - |
dc.title | Emergence of serotype 10A-ST11189 among pediatric invasive pneumococcal diseases, South Korea, 2014-2019 | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000697501500011 | - |
dc.identifier.doi | 10.1016/j.vaccine.2021.08.072 | - |
dc.identifier.bibliographicCitation | Vaccine, v.39, no.40, pp.5787 - 5793 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85113854745 | - |
dc.citation.endPage | 5793 | - |
dc.citation.startPage | 5787 | - |
dc.citation.title | Vaccine | - |
dc.citation.volume | 39 | - |
dc.citation.number | 40 | - |
dc.contributor.affiliatedAuthor | Cho, Hye-Kyung | - |
dc.type.docType | Article in Press | - |
dc.subject.keywordAuthor | Children | - |
dc.subject.keywordAuthor | Genotype | - |
dc.subject.keywordAuthor | Serotype | - |
dc.subject.keywordAuthor | Streptococcus pneumoniae | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.